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Abstract
Background: Clinical trial registries can improve the validity of trial results by facilitating comparisons between
prospectively planned and reported outcomes. Previous reports on the frequency of planned and reported outcome
inconsistencies have reported widely discrepant results. It is unknown whether these discrepancies are due to
differences between the included trials, or to methodological differences between studies. We aimed to systematically
review the prevalence and nature of discrepancies between registered and published outcomes among clinical trials.
Methods: We searched MEDLINE via PubMed, EMBASE, and CINAHL, and checked references of included publications
to identify studies that compared trial outcomes as documented in a publicly accessible clinical trials registry with
published trial outcomes. Two authors independently selected eligible studies and performed data extraction. We
present summary data rather than pooled analyses owing to methodological heterogeneity among the included
studies.
Results: Twenty-seven studies were eligible for inclusion. The overall risk of bias among included studies was
moderate to high. These studies assessed outcome agreement for a median of 65 individual trials (interquartile
range [IQR] 25–110). The median proportion of trials with an identified discrepancy between the registered and
published primary outcome was 31 %; substantial variability in the prevalence of these primary outcome discrepancies
was observed among the included studies (range 0 % (0/66) to 100 % (1/1), IQR 17–45 %). We found less variability within
the subset of studies that assessed the agreement between prospectively registered outcomes and published outcomes,
among which the median observed discrepancy rate was 41 % (range 30 % (13/43) to 100 % (1/1), IQR 33–48 %).
The nature of observed primary outcome discrepancies also varied substantially between included studies. Among the
studies providing detailed descriptions of these outcome discrepancies, a median of 13 % of trials introduced a new,
unregistered outcome in the published manuscript (IQR 5–16 %).
Conclusions: Discrepancies between registered and published outcomes of clinical trials are common regardless of
funding mechanism or the journals in which they are published. Consistent reporting of prospectively defined outcomes
and consistent utilization of registry data during the peer review process may improve the validity of clinical trial
publications.
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Background
The designation of a clearly defined, pre-specified primary
outcome is a critically important component of a clinical
trial [1]. Inconsistencies between planned and reported
outcomes threaten the validity of trials by increasing the
likelihood that chance or selective reporting, rather than
true differences between treatment and control groups,
account for primary outcome differences as reported at
the time of publication. These inconsistencies can have
direct consequences for physician decision-making and
policies that influence patient care [2].
ClinicalTrials.gov was established in 2000, in large part
to encourage consistency and transparency in the report-
ing of clinical trial outcomes. Since 2005 the International
Committee of Medical Journal Editors (ICMJE) has expli-
citly supported this goal by mandating the registration of
clinical trials in a publicly available registry prior to begin-
ning trial enrollment as a condition of publication in
member journals [3]. Additionally, both the United States
and the European Union have passed legislation requiring
the prospective registration of most clinical trials involving
drugs or devices [4, 5]. As a result of these policies, trial
registration has dramatically increased [6], and registries
are now important tools for assessing consistency between
planned and published primary outcomes.
Reported discrepancy rates between registered clinical
trial outcomes and published outcomes range from less
than 10 % of trials to greater than 60 % [7–9]. It is un-
known whether this wide range in results stems from
differences in characteristics of the included trials or
from differences in how investigators assessed outcome
consistency. It is also unclear which estimates are most
representative of clinical trials in general. A better under-
standing of the problem of outcome inconsistencies may
help define the frequency and impact of inappropriate
changes to trial outcomes and identify subgroups of clin-
ical trials that warrant further attention. Additionally, this
knowledge may help inform future regulations aimed at
improving trial transparency. We conducted a systematic
review of published comparisons of registered and pub-
lished primary trial outcomes in order to provide a com-
prehensive assessment of the observed prevalence and
nature of outcome inconsistencies.
Methods
Search strategy and study selection
We performed a search for studies that evaluated the agree-
ment between primary trial outcomes as documented in
clinical trials registries and as described in published manu-
scripts. Studies were eligible if they included data from clin-
ical trials, utilized either ClinicalTrials.gov or any registry
meeting World Health Organization (WHO) Registry Cri-
teria (Version 2.1), and included comparisons to outcomes
as defined in published manuscripts. We excluded studies
published prior to 2005, because our objective was to
characterize inconsistencies between trial registries and
publications, and registries were used infrequently prior to
the 2005 ICMJE statement requiring trial registration. Man-
uscripts were also excluded if they were secondary reports
of studies for which the relevant findings had previously
been published, or if they were published in a language
other than English. Reports of individual trials, case reports,
and editorials were excluded. We searched MEDLINE via
PubMed and CINAHL in August 2014, and EMBASE in
September 2014. Full details from each search are available
in Additional file 1: Appendix A. Additionally, we reviewed
the citation lists from each included manuscript for add-
itional eligible studies.
Two investigators (LGK, WCH) independently screened
the titles and abstracts of manuscripts identified through
the database searches to identify potentially eligible studies
for further assessment. Discrepancies were resolved by a
third investigator (CWJ). Following this step, two inves-
tigators then independently assessed each remaining
full-length manuscript for inclusion in the study. A
third investigator again reviewed all discrepancies, and
the final list of included studies was determined by
group consensus.
The primary outcome of interest for this systematic re-
view was the proportion of trials in which the registered
and published primary outcomes were different. Second-
ary outcomes were differences between registered and
published secondary outcomes and the relationship be-
tween registered and published outcomes on the statis-
tical significance of published outcomes.
Data extraction
Two investigators independently performed data extraction
for each eligible study using a standardized data form. For
each study, investigators recorded the total number of tri-
als examined and the number of trials for which a discrep-
ancy was present between the registered and published
primary outcome. WHO-approved trial registries must
save a history of changes made to registry records, and we
also recorded whether study authors reported reviewing
these changes. When included studies utilized this feature
to report registered outcomes at various time points, we
used the primary outcome registered at the time enroll-
ment started as the registered outcome [3]. Additional data
fields included the nature of primary outcome discrepan-
cies, categorized according to a modified version of the ap-
proach developed by Chan et al. [10] These categories are:
a registered primary outcome was omitted in the manu-
script; an unregistered primary outcome was introduced in
the manuscript; a registered primary outcome was de-
scribed as a secondary outcome in the manuscript; a pub-
lished primary outcome was described as a secondary
outcome in the registry; and the time of primary outcome
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assessment differed between the registry and manuscript.
When possible, the data abstractors also recorded informa-
tion about the publishing journals or clinical specialties for
trials included in each study, publication year of included
trials, registry databases utilized for each study, the timing
of trial registration with respect to participant enrollment,
and the proportion of outcome discrepancies favoring stat-
istical significance in a published manuscript.
Data synthesis
Data were analyzed in accordance with the methodology
recommended in the Cochrane Handbook for Systematic
Reviews of Interventions, where relevant, and results are re-
ported in accordance with the Preferred Reporting Items
for Systematic Reviews and Meta-Analyses (PRISMA) state-
ment (Additional file 2: Appendix B) [11, 12]. For each in-
cluded study we calculated the proportion of trials with
primary outcome discrepancies, along with 95 % confidence
intervals. Significant heterogeneity with respect to the
methods of the included studies and substantial statistical
heterogeneity prevented us from performing pooled ana-
lyses. Pre-specified analyses included the assessment of
primary outcome discrepancies among prospectively
registered trials, secondary outcome discrepancies, and
the proportion of outcome discrepancies favoring stat-
istical significance in a published manuscript. Following
our initial data analysis, we decided to compare primary
outcome discrepancy rates between studies in which au-
thors generated a list of published trials and searched for
corresponding registry entries with studies in which a list
of registered trials was used as the basis for a publication
search, because both strategies were common among the
included studies.
We assessed the risk of bias of included studies using a
modified version of the Newcastle-Ottawa Scale for asses-
sing the quality of cohort studies, in which the included
studies were assessed based on the following factors: rep-
resentativeness of the included cohort; ascertainment of
the link between trial registry and manuscript; method of
assessing primary outcome agreement; enrollment win-
dow of included trials; and the analysis of prospectively
registered outcomes (Additional file 3: Appendix C)
[13]. We used the Wilson score method with continuity
correction to calculate 95 % confidence intervals [14].
Analyses were conducted using Stata 14 (College Sta-
tion, TX, USA).
Results
Description of included studies
Database searches identified 5208 records. Following ex-
clusions based on title and abstract review, we assessed 57
full manuscripts for eligibility. Twenty-five studies identi-
fied by the database search and another two studies identi-
fied through the citation review met inclusion criteria for
a total of 27 eligible studies that compared registered and
published primary outcomes (Fig. 1) [7–9, 15–38]. Char-
acteristics of these studies, including publication dates, a
description of included trials, and search methods, are re-
ported in Table 1. Detailed ratings regarding risk of bias
for the included studies are provided in Additional file 3:
Appendix C. Risk of bias was moderate to high for most
Fig. 1 Flowchart of study selection process
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Table 1 Characteristics of included studies
Authors Journal and
publication year
Publication
dates of
included
trials
Trials registries
used
Description of
included trials
Trials
included in
outcome
consistency
assessment
Date of
initial
registry
search
Method of
identifying
included
studies
Used
prospectively
registered
outcomes in
discrepancy
analysis
Method of
characterizing
outcome
discrepancies
Subgroup
analyses
Additional
comparisons
between
registry and
manuscript
Anand et al.
[16]
Intensive Care
Med. 2014
2005–2011 ClinicalTrials.gov,
ISRCTN,
anzctr.org.au
Critical care trials 55 Unknown Publication
search
Yes Not
applicable
Journals following
ICMJE
recommendations
Sample size
Bourgeois et al.
[17]
Ann Intern Med.
2010
Not
available
ClinicalTrials.gov Trials of
anticholestermics,
antidepressants,
antipsychotics,
proton pump
inhibitors,
vasodilators
85 31 August
2009
Registry
search
No Not
applicable
Funding source None
Chahal et al.
[18]
Am J Sports Med.
2012
Not
available
ClinicalTrials.gov Orthopedic sports
medicine trials
20 Unknown Registry
search
No Modified
version of
Chan’s
classification
None Sample size,
inclusion
criteria
Ewart et al. [15] Ann Fam Med.
2009
2006–2007 ClinicalTrials.gov,
ISRCTN,
anzctr.org.au,
national register
for included
trials
Trials in high-
impact journals
110 Unknown Publication
search
No Chan None None
Gandhi et al.
[19]
BMC Musculoskelet
Disord. 2011
1999–2010 ClinicalTrials.gov Trials related to
orthopedic
trauma
20 July 2010 Registry
search
No Chan Funding source Sample size
Hannink et al.
[20]
Ann Surg. 2013 2007–2012 ClinicalTrials.gov,
ISRCTN,
anzctr.org.au,
“Other”
Trials assessing
surgical
interventions
152 Unknown Publication
search
Yes Chan General medical
vs surgical
journals
None
Hartung et al.
[21]
Ann Intern Med.
2014
Not
available
ClinicalTrials.gov Random sample
of phase 3 or 4
trials completed
before January
2009 with results
available in
ClinicalTrials.gov
110 15
February
2011
Registry
search
No Not
applicable
None Results,
adverse
events
Huić et al. [22] PLoS One. 2011 2005–2005 ClinicalTrials.gov Trials in ICMJE
member journals
152 Unknown Publication
search
Yes Chan None Title, start
date, trial
methods,
sample size
Hutfless et al.
[23]
Abstract from
American
Gastroenterological
Not
available
ClinicalTrials.gov Trials of Crohn’s
disease
medications
25 July 2010 Unknown No Not
applicable
None None
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Table 1 Characteristics of included studies (Continued)
Association 2013
meeting
Jones et al. [24] Ann Emerg Med.
2012
2008–2011 ClinicalTrials.gov,
ISRCTN, WHO
portal, national
register for
included trials
Trials published in
emergency
medicine journals
57 Unknown Publication
search
Yes Chan None None
Khan et al. [25] Arthritis Rheum.
2012
2002–2007 ClinicalTrials.gov Trials of drug
therapy for rheumatoid
arthritis
6 Unknown Publication
search
No Not
applicable
None None
Killeen et al.
[26]
Ann Surg. 2014 2009–2010 ClinicalTrials.gov,
ISRCTN, WHO
portal, national
register for
included trials
Trials from surgical
journals
108 Unknown Publication
search
No Chan None None
Li et al. [27] Scand J
Gastroenterol. 2013
2009–2012 “Registries
accepted by the
ICMJE”
Gastroenterology
trials
155 Unknown Publication
search
No Chan General medical
vs
gastroenterology
& hepatology
journals
None
Liu et al. [28] BMJ Open. 2013 Not
available
WHO registry
portal plus
Korean Clinical
Research
Information
Service
Trials of traditional
Chinese medicine
65 July 2012 Registry
search
No Not
applicable
None Sample size,
study
methods
Mathieu et al.
[7]
JAMA. 2009 2008 ClinicalTrials.gov,
ISRCTN, WHO
portal, national
register for
included trials
Cardiology, rheumatology,
and gastroenterology
trials in high-impact
general medical and
specialty journals
147 Unknown Publication
search
Yes Chan General medical
vs specialty
journals
None
Mathieu et al.
[29]
Joint Bone Spine.
2012
2006–2008 ClinicalTrials.gov,
ISRCTN
Trials on
rheumatoid arthritis,
osteoarthritis, and
spondyloarthropathies
40 Unknown Publication
search
No Not
applicable
None None
Milette et al.
[30]
J Psychosom Res.
2011
2008–2009 ClinicalTrials.gov,
ISRCTN, WHO
portal, national
register for
included trials
Trials in
psychosomatic and
behavioral health
journals
1 Unknown Publication
search
Yes Not
described
None None
Nankervis et al.
[31]
J Invest Dermatol.
2012
2007–2011 WHO portal Eczema trials from
the Global Resource
for Eczema Trials
(GREAT) database
8 Unknown Publication
search
Yes Differences in
primary and
published
outcomes or
outcome
timing
None None
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Table 1 Characteristics of included studies (Continued)
Pinto et al. [32] Phys Ther. 2013 2009 ClinicalTrials.gov,
ISRCTN, WHO
portal,
anzctr.org.au,
national register
for included
trials
Physical therapy trials
indexed in the
Physiotherapy Evidence
Database (PEDro)
62 Unknown Publication
search
No Chan None None
Rosenthal et al.
[33]
Ann Surg. 2013 2010 ClinicalTrials.gov,
ISRCTN, WHO
portal
Trials from high
impact general
surgical journals
51 Unknown Publication
search
No Chan Funding source,
registration
timing
Trial
methods,
sample size,
analytical
plan
Ross et al. [8] PLoS Med. 2009 Not
available
ClinicalTrials.gov Random sample of
phase 2–4 trials
registered in
ClinicalTrials.gov and
completed by June
2007
198 Unknown Registry
search
No Not
applicable
None None
Smith et al. [34] J Arthroplasty.
2012
2006–2011 ClinicalTrials.gov Arthroplasty trials 25 July 2010 Registry
search
No Chan Funding source Sample size
Smith et al. [9] Pain. 2013 2002–2011 ClinicalTrials.gov Trials from the
Repository of
Registered Analgesic
Clinical Trials
79 1
December
2011
Registry
search
No Chan Funding source,
trial phase
Analytical
plan,
missing
data plan
Vera-Badillo
et al. [35]
Ann Oncol. 2013 1995–2011 ClinicalTrials.gov Breast cancer trials 30 Unknown Publication
search
No Not
applicable
Funding source None
Walker et al.
[36]
JRSM Open. 2014 2011–2012 ClinicalTrials.gov,
ISRCTN, national
register based
on first author
nationality
Trials from the Journal
of the American
Medical Association
and BMJ
75 Unknown Publication
search
Yes Chan None Sample size,
analytical
plan
Wildt et al. [37] BMJ Open. 2011 1980–2011 ClinicalTrials.gov Trials on diseases of
the digestive system
66 1 January
2009
Registry
search
No Not
described
None Sample size
You et al. [38] J Clin Oncol. 2012 2005–2009 ClinicalTrials.gov,
ISRCTN
Adult solid tumor
oncology trials
134 August
2009
Publication
search
No Not
applicable
Funding source,
journal impact
factor,
publication year,
location of
author
None
ISRCTN International Standard Randomised Controlled Trial Number registry, ICMJE International Committee of Medical Journal Editors, WHO World Health Organization
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studies; five studies were judged to be at low risk of bias
[7, 16, 20, 24, 30].
Among the included studies, the median number of tri-
als assessed for outcome discrepancies was 65 (interquar-
tile range [IQR] 25–110), and the median proportion of
studies for which a discrepancy was identified between the
registered and published primary outcome was 31 %,
though this varied substantially across the included studies
(range 0 % [0/66] to 100 % [1/1], IQR 17–45 %; Fig. 2).
Sixteen studies provided detailed information about
the nature of observed outcome discrepancies (Table 2).
Among these studies, discrepancies fitting each of the five
categories described by Chan et al. were common [10]: for
five studies the most common discrepancy was omission of
a registered primary outcome [15, 19, 20, 30, 34]; for four
studies the most common discrepancy was publication of
an unregistered primary outcome [7, 22, 31, 36]; one study
reported equal numbers of these two types of discrepancies
[26]; for three studies the most commonly observed dis-
crepancy was reporting the registered primary outcome as
a secondary outcome [18, 24, 27]; and for three studies
the most common discrepancy was a change in the tim-
ing of primary outcome assessment [9, 32, 33].
Subgroup analyses within included studies
Nine studies compared registered and published primary
outcomes for trials that received industry funding and those
that did not. One study observed that industry sponsored
trials were significantly less likely to have outcome incon-
sistencies than were trials with other funding sources [17].
The remaining eight studies observed no significant rela-
tionship between funding source and outcome consistency
[9, 15, 16, 24, 33–35, 38].
The authors of three studies compared primary outcome
consistency between general medical journals and specialty
journals. Of these, one study compared trials published in
general medical journals to those published in specialty
surgical journals, finding a higher rate of outcome incon-
sistencies among trials published in the surgical journals
[20]. Another study compared trials published in general
medical journals to those in gastroenterology journals, and
the remaining study compared trials from general medical
journals with those published in cardiology, rheumatology,
or gastroenterology specialty journals. Neither of the latter
two studies observed a difference in discrepancy rate ac-
cording to journal type [7, 27].
Eight studies analyzed the impact that changes to regis-
tered primary outcomes had on the statistical significance
of published primary outcomes for included trials (Fig. 3);
an additional study reported the impact of an outcome
change for a single trial, finding this change to favor statis-
tical significance of the published outcome [30]. When it
could be assessed, outcome changes frequently favored the
publication of statistically favorable results (median 50 %,
Fig. 2 Forest plot showing the proportion of registered and published primary outcome discrepancies among included studies. Horizontal bars
indicate 95 % confidence intervals (CI) for proportions
Jones et al. BMC Medicine  (2015) 13:282 Page 7 of 12
IQR 28–64 %). However, in as many as half of the in-
cluded trials, the impact of outcome changes on the fa-
vorability of the published results could not be assessed
[7]. Consequently, these data likely underestimate the
true impact of outcome changes on the reported favor-
ability of published results.
Heterogeneity among studies
We performed several additional analyses in order to ex-
plore the substantial variability in reported outcome agree-
ment between included studies. Of the five studies judged
to be at low risk of bias, one included an outcome com-
parison from just a single trial, finding the registered and
Table 2 Nature of reported primary outcome discrepancies
Study Included trials;
N
Published articles
with new primary
outcome; N (%)
Registered primary
outcome not reported
in published article;
N (%)
Registered primary
outcome reported
as secondary in
published article; N (%)
Published primary
outcome described
as secondary in
registry; N (%)
Timing of primary
outcome assessment
differs between registry
and article; N (%)
Chahal et al., 2012 [18] 20 3 (15) 4 (20)
Ewart et al., 2009 [15] 110 10 (9) 20 (18) 6 (5) 3 (3)
Gandhi et al., 2011 [19] 20 0 (0) 2 (10) 0 (0) 0 (0)
Hannink et al., 2013 [20] 152 24 (16) 32 (21) 8 (5) 14 (9) 9 (6)
Huić et al., 2011 [22] 152 49 (32) 2 (1) 7 (5) 1 (1)
Jones et al., 2012 [24] 57 9 (16) 3 (5) 10 (18) 9 (16) 5 (9)
Killeen et al., 2014 [26] 108 9 (8) 9 (8) 6 (6) 6 (6) 7 (6)
Li et al., 2013 [27] 155 7 (5) 5 (3) 9 (6) 6 (4) 6 (4)
Mathieu et al., 2009 [7] 147 22 (15) 15 (10) 6 (4) 8 (5) 4 (3)
Milette K et al., 2011 [30] 1 0 (0) 1 (100) 0 (0) 0 (0) 0 (0)
Nankervis et al., 2012 [31] 8 2 (25) 1 (13)
Pinto et al., 2013 [32] 62 12 (19) 8 (13) 17 (27) 6 (10) 18 (29)
Rosenthal et al., 2013 [33] 51 10 (20) 9 (18) 11 (22) 7 (14) 12 (24)
Smith et al., 2012 [34] 25 2 (8) 3 (12) 2 (8)
Smith et al., 2013 [9] 79 4 (5) 5 (6) 6 (8) 2 (3) 38 (48)
Walker et al., 2014 [36] 75 10 (13) 2 (3) 2 (3) 1 (1) 5 (7)
Wildt et al., 2011 [37] 66 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Totals 1288 173 (13) 116 (9) 94 (7) 63 (5) 105 (8)
Not all studies provided data for each possible category
Fig. 3 Forest plot showing the proportion of trials with primary outcome changes favoring statistically significant published outcomes. Horizontal
bars indicate 95 % confidence intervals (CI) for proportions
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published outcomes to be discrepant [30]. The other four
studies identified outcome discrepancies in between 27 %
(15/55) and 49 % (75/152) of trials [7, 16, 20, 24]. The 22
studies determined to be at moderate to high risk of bias
showed less consistency in their reported outcome discrep-
ancies, ranging from 0 % (0/66) to 92 % (23/25), with a me-
dian discrepancy rate of 29 % (IQR 14–38 %).
Only one study explicitly limited inclusion to trials com-
pleted after the 2005 deadline for registration established
by the ICMJE [16], and none limited inclusion to trials
completed after the 2007 U.S. Food and Drug Administra-
tion Amendment Act expanded registration requirements
and authorized civil fines for unregistered trials. However,
eight studies limited inclusion to trials published after
2007 [7, 24, 26, 27, 30, 32, 33, 36]. Among these eight
studies, the incidence of primary outcome changes be-
tween registry entries and manuscripts was similar to the
findings observed among all included studies, with a me-
dian discrepancy rate of 38 % (IQR 30–50 %).
Eight of the included studies examined the history of
changes made to each registry record in order to compare
published outcomes with the primary outcome as stated in
the registry at either the time of study initiation or prior to
completion of enrollment [7, 16, 20, 22, 24, 30, 31, 36]. In
six of these cases, outcome discrepancy data were available
specifically for trials that had been prospectively registered.
Among these studies, the median proportion of prospect-
ively registered studies with discrepancies between the
registry and published manuscript was 41 % (range 30 %
[13/43] to 100 % [1/1], IQR 33–48 %), and the lowest re-
ported discrepancy rate was 30 % (Fig. 4). One study, pub-
lished only in abstract form, used the ClinicalTrials.gov
history of changes feature to identify trials with consistent
outcomes at each of three time points (registry entry at
time of initial registration, publication, current registry
entry as of July 2010) and found discrepancies in 23 of 25
randomized controlled trials (92 %) [23]. The remaining 18
studies compared the current registry entry with the pub-
lished outcome and did not take into account registry
changes over time; among these the median primary out-
come discrepancy rate was 26 % (IQR 14–34 %). The
higher observed discrepancy rate among studies that exclu-
sively utilized prospectively defined outcomes suggests that
registered outcomes are often retrospectively changed to
match published outcomes. This observation also likely
contributes to heterogeneity in the reported results among
the studies included in this analysis.
In order to match registry data with published manu-
scripts, 17 studies began with a cohort of published trials
and searched trial registries to identify registry entries cor-
responding to these published manuscripts. Among these
studies, the rate of unregistered trials ranged from 1 % to
94 % (median 38 %, IQR 20–71 %). Among the six studies
that reported detailed results on the timing of randomized
controlled trial registration, compliance with the ICMJE
policy requiring prospective trial registration was poor
[16, 22, 24, 27, 32, 33]. The median observed rate of pro-
spective registration in these six studies was 15 % (range
9–31 %). Nine studies began with a group of registered tri-
als and searched for corresponding publications [8, 9, 17–
19, 21, 28, 34, 37], and one study did not specify which
method was used [23]. The median percentage of primary
outcome discrepancies among the 17 studies in which au-
thors generated a list of published trials and searched for
corresponding registry entries was 32 % (IQR 25–45 %),
as compared to 18 % (IQR 6–32 %) among the nine stud-
ies in which a list of registered trials was used as the basis
for a publication search.
Additional analyses
The authors of the included studies observed high rates of
ambiguity in the way primary outcomes were defined in
Fig. 4 Forest plot showing the proportion of primary outcome discrepancies among prospectively registered trials. Horizontal bars indicate 95 %
confidence intervals (CI) for proportions
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registry entries. Eighteen of the 27 studies reported the
number of included registry entries in which primary out-
comes were undefined or unclear, with rates of ambigu-
ously defined outcomes ranging from 4 % to 48 %
(median 15 %, IQR 7–27 %) [7–9, 15, 17, 20, 22, 24, 26,
28–32, 34, 36–38]. In many cases this ambiguity was
noted to limit assessments of outcome consistency. In-
consistencies between registered and published second-
ary outcomes were also common. Ten studies evaluated
the consistency of secondary outcomes; the median rate
of observed secondary outcome discrepancies among
these studies was 54 % (IQR 33–68 %) [15, 18, 19, 21,
22, 28, 32–34, 37].
Discussion
We identified 27 studies that compared registered and
published trial outcomes. Among these studies, the
proportion of discrepant primary outcomes between
registration and publication was highly variable, with
four studies observing outcome changes in more than
50 % of trials, and eight studies observing outcomes
changes in fewer than 20 %. The frequency with which
discrepancies were identified did not appear to vary
based on funding source, journal type, or when trials
were published, though our ability to detect potential
differences was limited by relatively small sample sizes
and unstandardized methods across the included stud-
ies. Most of the studies identified were similar in regard
to the time frame analyzed and the journals and clinical
topics studied. Additionally, nearly all of the included
studies used a consistent method of categorizing out-
come differences, based on the scheme established by
Chan et al. [10]. One important source of the variability
in reported results is that most studies compared pub-
lished outcomes to the outcome listed in the registry at
the time of the search, without attempting to identify
the outcome registered at the inception of the study.
For the six studies that compared published outcomes
with the outcomes registered prior to the initiation of
patient enrollment, the frequency of discrepancies were
more similar to one another and higher than for the
remaining 21 studies. Because the comparison with the
outcome prior to patient enrollment is the most rele-
vant for those attempting to understand the impact of
outcome switching on the validity of results of clinical
trials, the median value from these six studies (41 %,
IQR 33–48 %) provides an informative estimate for
characterizing the extent of this problem.
This finding supports previous observations that registry
entries are often either initiated or modified after trial com-
pletion [7, 22]. Additionally, it suggests that for surveillance
studies of registry practices to be meaningful and reprodu-
cible, authors should utilize best practices to improve study
validity. These include assessing changes to registry entries
over time, establishing clear definitions for discrepant out-
comes, and utilizing multiple independent raters to com-
pare registered and published outcomes.
While clinical trial registries and recent legislative efforts
mandating their use have the potential to improve registry
utilization by trial sponsors and investigators, these mea-
sures do little good unless reviewers, journal editors, and
educators utilize them. Recent evidence suggests that re-
viewers do not routinely use trials registries when assessing
trial manuscripts [39]. In some cases there are good rea-
sons to change study outcomes or other methodological
details while a trial is ongoing, though it is critical that
published manuscripts disclose and explain these changes.
Other times, outcome changes may represent efforts by in-
vestigators to spin favorable conclusions from their data. In
either case, reviewers and editors can and should use regis-
try data to ensure that appropriate outcome changes are
transparent and that inappropriate changes are prevented.
All but one of the studies included clinical trials that
were initiated before 2005, which was when the ICMJE
policy mandating prospective trial registration as a condi-
tion of publication in member journals went into effect.
Registry utilization has increased dramatically since that
time, but the quality of registry data remains inconsistent
[22, 24]. The single study we examined that was limited to
trials initiated after the ICMJE statement still found pri-
mary outcome inconsistencies in 15 of 55 (27 %) included
trials [16]. Importantly, we did not find evidence of a con-
sistent difference in registered and published outcomes ac-
cording to trial funding source. As a result, any measures
taken to improve the consistency of outcome reporting
should target both industry-funded and non-industry-
funded trials. As registry utilization continues to evolve, it
is unclear whether outcome consistency will improve or
whether inconsistencies will remain common. It is likely
that this depends in part on the willingness of both jour-
nal editors and reviewers to demand that authors are held
accountable to registered protocols when publishing re-
sults. Unfortunately, very few journals currently prioritize
the assessment of registry entries during the peer review
process [40].
Since 2008, in addition to facilitating the assessment of
methodological consistency, Clinicaltrials.gov has included
a results database that allows the registry to serves as a
publicly available source of trial outcome data. While
utilization of the results database on the part of investiga-
tors has been mixed, improved compliance with this fea-
ture has the potential to streamline comparisons between
planned and completed outcome analyses [41]. Future
surveillance studies will be needed to assess improvements
in outcome consistency that might result from new pol-
icies, greater familiarity of investigators and sponsors with
the registry process, and greater scrutiny of registries by
editors and reviewers.
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Our findings are consistent with those reported in a
2011 Cochrane Review of studies comparing trial proto-
cols with published trial manuscripts [42]. This Cochrane
Review identified three studies, all also included in our
analysis, that compared registered primary outcomes to
published outcomes, with observed primary outcome dis-
crepancy rates between 18 % and 31 %. Additionally, the
Cochrane Review identified three studies that compared
the consistency between outcomes identified in study
protocols and those in published reports, finding dis-
crepancies in 33–67 % of included trials. As with our
review, the presence of heterogeneous trial populations
and methods prevented the Cochrane authors from
performing a meta-analysis, though they observed that
discrepancies between study protocols and published
manuscripts commonly involved other important as-
pects of trial design in addition to outcome definitions,
including eligibility criteria, sample size goals, planned
subgroup analyses, and methods of analysis.
This systematic review has several limitations that should
be considered when interpreting these results. First, studies
involving outcome discrepancies are challenging to capture
via a database search, because relevant studies are not lim-
ited to a single disease process or intervention, and many
of the key words relevant to this topic are commonly in-
cluded in unrelated abstracts (e.g., “bias,” “primary out-
come,” “clinicaltrials.gov,” “randomized controlled trial”).
We addressed this issue by using an intentionally broad
search strategy, and by reviewing the reference lists of all
included studies. Despite this, we may have missed some
relevant publications. Second, the studies identified were
heterogeneous with respect to both the characteristics of
their included trials and the approaches they used to assess
outcome consistency. This limits our ability to pool the
data to provide a summary description of discrepancies in
registered and published outcomes for trials across these
studies. This heterogeneity results partly from the variable
time points relative to trial initiation used by authors in de-
fining the registered outcome, and is indicative of possible
bias in these results at the level of individual studies. Third,
we separately analyzed the subgroup of studies that re-
ported reviewing the history of changes within each registry
record in order to identify prospectively defined outcomes;
this subgroup analysis may have been incomplete because
it is possible that additional studies performed this task
without reporting it. Further, several of the included studies
had overlapping inclusion criteria, and as a result in some
cases individual studies may have been included in more
than one study. Additionally, the impact of publication
bias on these results is unknown. Finally, many of the
included studies noted that ambiguously defined out-
comes among trial registries and manuscripts made it
difficult to make judgments about whether outcome
differences were present.
Conclusions
Published randomized controlled trials commonly report
primary outcomes that differ from the primary outcomes
specified in clinical trials registries. These inconsistencies
in published and reported outcomes are observed among
trials across a broad range of clinical topics and a variety
of funding sources. When assessing a trial’s methodo-
logical quality, editors, reviewers, and readers should rou-
tinely compare the published primary outcome to the
primary outcome registered at the time of trial initiation.
Further study, with attention to the outcome registered at
the time of trial initiation, is needed to determine whether
inconsistencies between registered and published out-
comes remain common among recently initiated trials.
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